Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension

By Steve Cummings, S. Ferrari, Richard Eastell, N. Gilchrist, J. Jensen, M. McClung, C. Roux, O. Törring, I. Valter, Andrea Wang and 1 more. Journal of Bone and Mineral Research, 2018

626 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/0bea70ff6aa15cfc74c8d0b5ecdfa63d7c3f90b0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Reginster
2. Chris Cooper
3. R. Rizzoli
4. on behalf of the International Osteoporosis Foundation
5. J. Kanis

In Orthopedics and Sports Medicine

1. J. Reginster
2. Chris Cooper
3. R. Rizzoli
4. on behalf of the International Osteoporosis Foundation
5. J. Kanis
6. Eugene V. McCloskey
7. H. Johansson
8. O. Johnell

Citations in the corpus

• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Studies indicate that discontinuing denosumab results in increased bone turnover markers, reduced BMD, and increased risk of multiple vertebral fractures, especially in patients with a prior vertebral fracture [192, 267].”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “[259], the vertebral fracture rate increased to a value similar to that observed in participantswho received and then discontinued placebo [262].”